News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|June 1, 2002

New Products

New products of interest to our readers

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

ByMorgan Ebert, Executive Editor

June 29th 2026

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression | Image credit: © New Africa - stock.adobe.com

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression

ByMorgan Ebert, Executive Editor

June 29th 2026

Pediatric clinical trial update: Q2 2026

Pediatric clinical trial update: Q2 2026

ByMorgan Ebert, Executive Editor

June 29th 2026

AAP updates guidance on pediatric iron deficiency screening and treatment | Image Credit: © nicoletaionescu - stock.adobe.com

AAP updates guidance on pediatric iron deficiency screening and treatment

ByMorgan Ebert, Executive Editor

June 29th 2026

FDA approves risankizumab for pediatric plaque psoriasis and psoriatic arthritis

FDA approves risankizumab for pediatric plaque psoriasis and psoriatic arthritis

ByMorgan Ebert, Executive Editor

June 26th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

AAP updates guidance on pediatric iron deficiency screening and treatment

Pediatric clinical trial update: Q2 2026

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

RSV Post-Authorization Data and Second-Season Protection: Emerging Evidence

FDA approves risankizumab for pediatric plaque psoriasis and psoriatic arthritis